RCUS

Arcus Biosciences, Inc. (RCUS) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Arcus Biosciences is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for cancer and immunology. The company has no approved products and generates revenue solely through collaboration and licensing agreements, primarily with Gilead Sciences and Taiho Pharmaceutical. As of July 30, 2026, there were 127.3 million shares of common stock outstanding.

Key Financial Metrics

Note: Q2 2025 net loss was effectively zero due to a $143 million revenue catch-up adjustment from a contract modification with Gilead.

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 74% in Q2 2026 compared to Q2 2025. This is primarily due to the absence of the $143 million cumulative catch-up revenue recognized in Q2 2025 following Gilead's termination of rights to the etrumadenant program. Current revenue is driven by access rights expirations and Taiho collaboration milestones.
• Increased Net Loss: The company reported a net loss of $91 million in Q2 2026, compared to break-even in Q2 2025. The loss widened due to the drop in revenue and continued operating expenses.
• Expense Reduction: Operating expenses decreased 18% year-over-year in Q2 2026. Research and Development (R&D) expenses fell 19% to $113 million, driven by the wind-down of Phase 3 studies for domvanalimab (STAR-121 and PACIFIC-8) and reduced partnership reimbursements.
• Liquidity Position: Cash, cash equivalents, and marketable securities decreased from $1.01 billion at year-end 2025 to $775 million as of June 30, 2026, reflecting operating cash burn and investment activity.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current cash and investments ($775 million) are sufficient to fund operations until at least the second half of 2028. The company has a $250 million term loan facility with Hercules Capital, of which $100 million has been drawn; an additional $150 million is available subject to clinical and regulatory milestones.
• Strategic Shifts:
  • Gilead Collaboration: Gilead's option rights to new pipeline programs expired on July 14, 2026, following a decision not to make the sixth-anniversary continuation payment. Gilead retains time-limited options on specific programs (AXL, CD39, TNF).
  • Program Discontinuations: The company discontinued the Phase 3 STAR-121 and PACIFIC-8 studies for domvanalimab due to futility in April and August 2026, respectively.
  • New Partnerships: Announced collaborations with Bristol Myers Squibb, Summit Therapeutics, and AVEO Oncology to evaluate casdatifan (HIF-2α inhibitor) in renal cell carcinoma.
• Risks: Key risks include the need for additional capital, reliance on third-party manufacturers (including WuXi Biologics in China), potential regulatory delays, and the speculative nature of clinical-stage development. The company faces covenants under its Hercules debt agreement that could restrict operations in an event of default.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $775 million cash balance against the projected burn rate, considering the wind-down of Gilead-funded programs and increased self-funding of casdatifan.
• Debt Covenants: Review the specific financial covenants in the Hercules Capital agreement, particularly the minimum cash requirements beginning July 2027.
• Casdatifan Progress: Monitor enrollment and data readouts for the new casdatifan collaborations (ROSETTA RCC-208, ARC-20) as this is now the primary late-stage asset.
• Manufacturing Supply Chain: Assess risks related to the U.S. BIOSECURE Act and potential restrictions on WuXi Biologics, the sole manufacturer of zimberelimab.
• Revenue Recognition: Understand the timing of future revenue from Taiho milestones and the expiration of Gilead access rights, as these are non-recurring or lumpy events.